IP Library Granted Patent US 7,459,538
Granted Patent B2
US 7,459,538 · App. 11/174,186 · Granted Dec 2, 2008

Recombinant tumor specific antibody and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,538
App. No.
11/174,186
Granted
Dec 2, 2008
Kind
B2
Abstract

The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.

Claims (16)

1. An anti-EpCAM protein comprising an antibody that binds human EpCAM, said antibody comprising an immunoglobulin light chain variable region comprising (i) amino acid residues 24-31 of SEQ ID NO:1; (ii) amino acid residues 49-55 of SEQ ID NO:1; and (iii) amino acid residues 88-96 of SEQ ID NO:1; and further comprising an amino acid sequence defining an immunoglobulin light chain framework region selected from the group consisting of: (i) amino acid residues 1-23 of SEQ ID NO:8; and (ii) amino acid residues 1-23 of SEQ ID NO:9.

2. The anti-EpCAM protein of claim 1 , wherein the antibody comprises amino acids 1-106 of SEQ ID NO:9.

3. The anti-EpCAM protein of claim 1 , wherein the antibody has a Kd for EpCAM of at least 10 −8 M.

4. The anti-EpCAM protein of claim 1 , wherein the protein comprises a cytokine.

5. The anti-EpCAM protein of claim 4 , wherein the cytokine is IL-2.

6. An anti-EpCAM protein, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin heavy chain variable region comprising (i) amino acid residues 26-35 of SEQ ID NO:2; (ii) amino acid residues 50-62 of SEQ ID NO:2; and (iii) amino acid residues 101-105 of SEQ ID NO:2; and further comprising an amino acid sequence defining an immunoglobulin heavy chain framework region selected from the group consisting of: (i) amino acid residues 1-25 of SEQ ID NO:18; and (ii) amino acid residues 67-98 of SEQ ID NO:18.

7. The anti-EpCAM protein of claim 6 , wherein the antibody comprises amino acids 1-116 of SEQ ID NO:18.

8. The anti-EpCAM protein of claim 6 , wherein the antibody has a Kd for EpCAM of at least 10 −8 M.

9. The anti-EpCAM protein of claim 6 , wherein the protein comprises a cytokine.

10. The anti-EpCAM protein of claim 9 , wherein the cytokine is IL-2.

11. An anti-EpCAM protein, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an antibody light chain comprising the amino acid sequence defined by residues 1-106 of SEQ ID NO:9 and an antibody heavy chain comprising the amino acid sequence defined by residues 1-116 of SEQ ID NO:18.

12. The anti-EpCAM protein of claim 11 , wherein the protein comprises a cytokine.

13. The anti-EpCAM protein of claim 12 , wherein the cytokine is IL-2.

14. A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin light chain variable region comprising (i) amino acid residues 24-31 of SEQ ID NO:1; (ii) amino acid residues 49-55 of SEQ ID NO:1; and (iii) amino acid residues 88-96 of SEQ ID NO:1; and further comprising an amino acid sequence defining an immunoglobulin light chain framework region selected from the group consisting of: (i) amino acid residues 1-23 of SEQ ID NO:8; and (ii) amino acid residues 1-23 of SEQ ID NO:9.

15. A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin heavy chain variable region comprising (i) amino acid residues 26-35 of SEQ ID NO:2; (ii) amino acid residues 50-62 of SEQ ID NO:2; and (iii) amino acid residues 101-105 of SEQ ID NO:2; and further comprising an amino acid sequence defining an immunoglobulin heavy chain framework region selected from the group consisting of: (i) amino acid residues 1-25 of SEQ ID NO:18; and (ii) amino acid residues 67-98 of SEQ ID NO:18.

16. A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an antibody light chain comprising the amino acid sequence defined by residues 1-106 of SEQ ID NO:9 and an antibody heavy chain comprising the amino acid sequence defined by residues 1-116 of SEQ ID NO:18.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2008
From: EMD LEXIGEN RESEARCH CENTER CORP.
To: MERCK PATENT GMBH
Reel/Frame 020451/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: GILLIES, STEPHEN D.; LO, KIN-MING; QIAN, XIUQI
To: EMD LEXIGEN RESEARCH CENTER CORP.
Reel/Frame 017840/0377 →